Trials / Completed
CompletedNCT05587699
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
A Randomized, Open-label, Multiple-dose and Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A in Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- Male
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
A study to evaluate the pharmacokinetics, pharmacodynamics, and safety of CKD-843 A in male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-843 A 45mg(Multiple dose) | 1 Injection/3 Month, 3 times Injections |
| DRUG | CKD-843 A 45mg | Single Injection |
| DRUG | CKD-843 A 55mg(Multiple dose) | 1 Injection/3 Month, 3 times Injections |
| DRUG | CKD-843 A 55mg | Single Injection |
| DRUG | CKD-843-R | 0.5mg/day, 9 Month |
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2023-09-15
- Completion
- 2023-10-17
- First posted
- 2022-10-20
- Last updated
- 2024-01-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05587699. Inclusion in this directory is not an endorsement.